Hasty Briefsbeta

The end of compounded GLP-1 drugs leaves many patients in a 'lose-lose' position

2 days ago
https://www.statnews.com/2025/04/29/compounded-glp-1-drugs-patients-seek-semaglutide-alternatives-wegovy-zepbound-mounjaro/
Copy Link
  • #healthcare access
  • #pharmaceutical industry
  • #GLP-1 drugs
  • The availability of compounded GLP-1 drugs is ending as regulators no longer consider branded drugs like Wegovy, Ozempic, and Mounjaro to be in shortage.
  • Patients who relied on compounded versions are now facing disruptions in care, with companies altering prescriptions, adding ingredients, or disappearing entirely.
  • Brand-name GLP-1 drugs cost around $1,000 per month, though Novo Nordisk and Eli Lilly now offer them at $350-$700 per month—still unaffordable for many who paid $200 for compounded versions.
  • Pharmaceutical companies are fighting compounders in court, citing safety concerns and viewing them as a threat to their obesity drug market, projected to reach $100 billion annually by 2030.
  • The FDA has received over 700 adverse event reports linked to compounded GLP-1s, though causality remains unclear.
AboutLogin